Treatment for Chronic Low Back Pain with Radiculopathy
For chronic low back pain with radiculopathy, gabapentin is the only medication with fair evidence for pain relief, though benefits are small and short-term; however, lumbosacral radiculopathy appears relatively refractory to most first-line neuropathic pain medications. 1
Pharmacologic Management
First-Line Medication Options
Gabapentin is the primary pharmacologic option specifically for radiculopathy, providing small, short-term benefits 1, 2. However, critical limitations exist:
- Only evaluated in 2 small, short-term placebo-controlled trials 2
- Has not been directly compared with other medications or treatments 1
- Not FDA-approved for low back pain with radiculopathy 1
Medications with Limited or Negative Evidence
NSAIDs: While effective for non-radicular chronic low back pain, evidence is insufficient specifically for radiculopathy 2
Tricyclic antidepressants: Recent trials of nortriptyline and morphine (and their combination) suggest lumbosacral radiculopathy may be refractory to these agents 3. Earlier guidelines recommended tricyclics for chronic low back pain generally 1, but newer evidence shows no difference versus placebo 4
Pregabalin: Recent negative trials indicate ineffectiveness for lumbosacral radiculopathy 3. An equivocal trial of topiramate also suggests limited benefit 3
Benzodiazepines: New evidence shows they are ineffective for radiculopathy and may actually increase pain compared to placebo 4
Systemic corticosteroids: Consistently ineffective across 6 trials for radicular low back pain, showing no differences from placebo in pain relief 4. Not recommended 1
Opioids: Use with Extreme Caution
Opioids show modest effects for chronic low back pain in short-term trials, but evidence specifically for radiculopathy is sparse 2. One small trial (36 patients) found an opioid with naproxen slightly superior to naproxen alone 2.
Critical considerations:
- Substantial risks including aberrant drug-related behaviors, abuse, and addiction 1
- High rates of adverse events, particularly constipation and sedation 2
- Should only be used judiciously when severe, disabling pain is not controlled with other options 1
- Failure to respond to a time-limited course should lead to reassessment and consideration of alternative therapies 1
Duloxetine: Emerging Option
Duloxetine shows small benefits for chronic low back pain generally (not specifically radiculopathy) 4. This represents newer evidence since the 2007 guidelines, though effects remain modest.
Important Clinical Pitfalls
The Radiculopathy Treatment Gap
Lumbosacral radiculopathy appears to be a peripheral neuropathic pain condition that is relatively refractory to existing first- and second-line neuropathic pain medications 3. This is a critical distinction from other neuropathic conditions like postherpetic neuralgia or diabetic peripheral neuropathy, where medications show clearer efficacy.
The consistency of negative trial results suggests that efficacy demonstrated in one neuropathic pain condition cannot be assumed to extrapolate to lumbosacral radiculopathy 3.
Functional Outcomes
Evidence of beneficial effects on functional outcomes is limited across all medication classes 2. Pain relief, when present, is typically small to moderate and short-term; improvements in function are generally smaller or not observed 4.
Non-Pharmacologic Considerations
Given the limited pharmacologic options, non-pharmacologic therapies become particularly important for chronic low back pain with radiculopathy. Guidelines recommend considering intensive interdisciplinary rehabilitation, exercise therapy, acupuncture, massage therapy, spinal manipulation, yoga, cognitive-behavioral therapy, or progressive relaxation 1.
For refractory cases, spinal cord stimulation may be effective, as patients with failed back surgery syndrome (many with lumbosacral radiculopathy) appear to respond to this modality 3. This suggests the condition is not generally refractory to all treatment modalities, just to most systemic medications.
Treatment Algorithm
- Start with gabapentin if neuropathic pain features predominate, recognizing benefits are small and short-term
- Avoid benzodiazepines and systemic corticosteroids (proven ineffective)
- Consider duloxetine if comorbid depression or if gabapentin fails
- Reserve opioids only for severe, disabling pain uncontrolled by other options, with careful monitoring and time-limited trials
- Emphasize non-pharmacologic therapies early given limited medication efficacy
- Reassess and refer if no improvement after 4 weeks or if red flags develop 1
The evidence clearly demonstrates that chronic low back pain with radiculopathy has fewer effective pharmacologic options than non-radicular chronic low back pain, necessitating a treatment approach that relies more heavily on non-pharmacologic interventions and careful patient selection for the limited medications that show any benefit.